Phenotype-associated changes in retinal pigment epithelial cell expression of insulin-like growth factor binding proteins

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 11, 2009, Pages 5449-5455

  Mukherjee, Sudipto ^a   King, Jeffery L ^b   Guidry, Clyde ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CYTOKERATIN 18; CYTOKERATIN 19; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN BINDING PROTEIN 6; VIMENTIN;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BIOSYNTHESIS; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIUM CELL; IMMUNOFLUORESCENCE; IMMUNOREACTIVITY; NONHUMAN; NORTHERN BLOTTING; PHENOTYPE; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SWINE; WESTERN BLOTTING;

ACTINS; ANIMALS; BIOLOGICAL MARKERS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELLS, CULTURED; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; KERATIN-18; KERATIN-19; MICROSCOPY, FLUORESCENCE; PHENOTYPE; RETINAL PIGMENT EPITHELIUM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SWINE; VIMENTIN;

EID: 77957313834     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-3383     Document Type: Article

References (63)

1. Pastor JC. Proliferative vitreoretinopathy: an overview. Surv Ophthalmol. 1998;43(1):3-18.
2. Charteris DG, Sethi CS, Lewis GP, et al. Proliferative vitreoretinopath- developments in adjunctive treatment and retinal pathology. Eye. 2002;16(4):369-374.
3. Pastor JC, de la Rua ER, Martin F. Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res. 2002;21(1): 127-144.
4. Ryan SJ. The pathophysiology of proliferative vitreoretinopathy in its management. Am J Ophthalmol. 1985;100(1):188-193.
5. Machemer R. Proliferative vitreoretinopathy (PVR): a personal account of its pathogenesis and treatment. Invest Ophthalmol Vis Sci. 1988;29:1771-1783.
6. Wiedemann P, Weller M. The pathophysiology of proliferative vitreoretinopathy. Acta Ophthalmol. 1988;189:4-15.
7. Campochiaro PA. Pathogenesis of proliferative vitreoretinopathy. In: Ryan SJ, ed. Retina. 3rd ed. St. Louis, MO: Mosby; 2001:2221-2227.
8. Grierson I, Mazure A, Hogg P, et al. Non-vascular vitreoretinopathy: the cells and the cellular basis of contraction. Eye. 1996;10(pt 6):671-684.
9. Vinores SA, Campochiaro PA, Conway BP. Ultrastructural and electron-immunocytochemical characterization of cells in epiretinal membranes. Invest Ophthalmol Vis Sci. 1990;31(1):14-28.
10. Baudouin C, Hofman P, Brignole F, et al. Immunocytology of cellular components in vitreous and subretinal fluid from patients with proliferative vitreoretinopathy. Ophthalmologica. 1991; 203(1):38-46.
11. Charteris DG. Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment. Br J Ophthalmol. 1995;79(10):953-960.
12. Casaroli-Marano RP, Pagan R, Vilaro S. Epithelial-mesenchymal transition in proliferative vitreoretinopathy: intermediate filament protein expression in retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 1999;40(9):2062-2072.
13. Grisanti S, Guidry C. Transdifferentiation of retinal pigment epithelial cells from epithelial to mesenchymal phenotype. Invest Ophthalmol Vis Sci. 1995;36(2):391-405.
14. Grisanti S, Guidry C, Heimann K. [Contraction of extracellular matrix by transdifferentiated retinal pigment epithelial cells, inducers and inhibitors]. Ophthalmologe. 1996;93(6):709-713.
15. Mamballikalathil I, Mann C, Guidry C. Tractional force generation by porcine Muller cells: paracrine stimulation by retinal pigment epithelium. Invest Ophthalmol Vis Sci. 2000;41(2):529-536.
16. Mukherjee S, Guidry C. The insulin-like growth factor system modulates retinal pigment epithelial cell tractional force generation. Invest Ophthalmol Vis Sci. 2007;48(4):1892-1899.
17. Peters MA, Burke JM, Clowry M, et al. Development of traction retinal detachments following intravitreal injections of retinal Muller and pigment epithelial cells. Graefes Arch Clin Exp Ophthalmol. 1986;224(6):554-563.
18. Yang CH, Huang TF, Liu KR, et al. Inhibition of retinal pigment epithelial cell-induced tractional retinal detachment by disintegrins, a group of Arg-Gly-Asp-containing peptides from viper venom. Invest Ophthalmol Vis Sci. 1996;37(5):843-854.
19. Wong CA, Potter MJ, Cui JZ, et al. Induction of proliferative vitreoretinopathy by a unique line of human retinal pigment epithelial cells. Can J Ophthalmol. 2002;37(4):211-220.
20. Lashkari K, Rahimi N, Kazlauskas A. Hepatocyte growth factor receptor in human RPE cells: implications in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1999;40(1):149-156.
21. Spraul CW, Kaven C, Amann J, et al. Effect of insulin-like growth factors 1 and 2, and glucose on the migration and proliferation of bovine retinal pigment epithelial cells in vitro. Ophthalmic Res. 2000;32(5):244-248.
22. Hinton DR, He S, Jin ML, et al. Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathy. Eye. 2002;16(4): 422-428.
23. Mitsuhiro MR, Eguchi S, Yamashita H. Regulation mechanisms of retinal pigment epithelial cell migration by the TGF-beta superfamily. Acta Ophthalmol Scand. 2003;81(6):630-638.
24. Miura Y, Yanagihara N, Imamura H, et al. Hepatocyte growth factor stimulates proliferation and migration during wound healing of retinal pigment epithelial cells in vitro. Jpn J Ophthalmol. 2003;47(3):268-275.
25. Spraul CW, Kaven C, Lang GK, et al. Effect of growth factors on bovine retinal pigment epithelial cell migration and proliferation. Ophthalmic Res. 2004;36(3):166-171.
26. Gamulescu MA, Chen Y, He S, et al. Transforming growth factor beta2-induced myofibroblastic differentiation of human retinal pigment epithelial cells: regulation by extracellular matrix proteins and hepatocyte growth factor. Exp Eye Res. 2006;83(1):212-222.
27. Hollborn M, Bringmann A, Faude F, et al. Signaling pathways involved in PDGF-evoked cellular responses in human RPE cells. Biochem Biophys Res Commun. 2006;344(3):912-919.
28. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995;16(1):3-34.
29. Conover CA. Regulation and physiological role of insulin-like growth factor binding proteins. Endocrine J. 1996;43(suppl):S43-S48.
30. Ferry RJ, Katz LEL, Grimberg A, et al. Cellular actions of insulin-like growth factor binding proteins. Hormone Metab Res. 1998;31: 192-202.
31. Ferry RJ, Cerri RW, Cohen P. Insulin-like growth factor binding proteins: new proteins, new functions. Hormone Res. 1999;51: 53-67.
32. Baxter RC. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab. 2000;278(6):E967-E976.
33. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002;23(6):824-854.
34. Duan C, Xu Q. Roles of insulin-like growth factor (IGF) binding proteins in regulating IGF actions. Gen Comp Endocrinol. 2005; 142(1-2):44-52.
35. Grant M, Russel B, Fitzgerald C, et al. Insulin-like growth factors in vitreous: studies in control and diabetic subjects with neovascularization. Diabetes. 1986;35:416-420.
36. Meyer-Schwickerath R, Pfeiffer A, Blum WF, et al. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease: studies in nondiabetic and diabetic subjects. J Clin Invest. 1993;92(6):2620-2625.
37. Boulton M, Gregor Z, McLeod D, et al. Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management. Br J Ophthalmol. 1997;81(3): 228-233.
38. Hardwick C, Feist R, Morris R, et al. Tractional force generation by porcine Muller cells: stimulation by growth factors in human vitreous. Invest Ophthalmol Vis Sci. 1997;38(10):2053-2063.
39. Spranger J, Buhnen J, Jansen V, et al. Systemic levels contribute significantly to increased intraocular IGF- I, IGF-II and IGF-BP3 [correction of IFG-BP3] in proliferative diabetic retinopathy. Horm Metab Res. 2000;32(5):196-200.
40. Guidry C, Feist R, Morris R, et al. Changes in IGF activities in human diabetic vitreous. Diabetes. 2004;53(9):2428-2435.
41. Schoen TJ, Beebe DC, Clemmons DR, et al. Local synthesis and developmental regulation of avian vitreal insulin-like growth factor- binding proteins: a model for independent regulation in extravascular and vascular compartments. Endocrinology. 1992; 131(6):2846-2854.
42. Arnold DR, Moshayedi P, Schoen TJ, et al. Distribution of IGF-I and -II, IGF binding proteins (IGFBPs) and IGFBP mRNA in ocular fluids and tissues: potential sites of synthesis of IGFBPs in aqueous and vitreous. Exp Eye Res. 1993;56(5):555-565.
43. Yang YW, Brown DR, Robcis HL, et al. Developmental regulation of insulin-like growth factor binding protein- 2 in chick embryo serum and vitreous humor. Regul Pept. 1993;48(1-2):145-155.
44. de la Rosa EJ, Bondy CA, Hernandez-Sanchez C, et al. Insulin and insulin-like growth factor system components gene expression in the chicken retina from early neurogenesis until late development and their effect on neuroepithelial cells. Eur J Neurosci. 1994; 6(12):1801-1810.
45. Waldbillig RJ, Jones BE, Schoen TJ, et al. Vitreal insulin-like growth factor binding proteins (IGFBPs) are increased in human and animal diabetics. Curr Eye Res. 1994;13(7):539-546.
46. Randolph A, Yee D, Feldman EL. Insulin-like growth factor binding protein expression in human retinal pigment epithelial cells. Ann N Y Acad Sci. 1993;692:265-267.
47. Feldman EL, Randolph AE. Regulation of insulin-like growth factor binding protein synthesis and secretion in human retinal pigment epithelial cells. J Cell Physiol. 1994;158(1):198-204.
48. Moriarty P, Boulton M, Dickson A, et al. Production of IGF-I and IGF binding proteins by retinal cells in vitro. Br J Ophthalmol. 1994;78(8):638-642.
49. Takagi H, Yoshimura N, Tanihara H, et al. Insulin-like growth factor-related genes, receptors, and binding proteins in cultured human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 1994;35(3):916-923.
50. Matsunaga H, Handa JT, Gelfman CM, et al. The mRNA phenotype of a human RPE cell line at replicative senescence. Mol Vis. 1999;5:39.
51. Miyamura N, Mishima K, Honda S, et al. Age and topographic variation of insulin-like growth factor-binding protein 2 in the human RPE. Invest Ophthalmol Vis Sci. 2001;42(7):1626-1630.
52. King JL, Guidry C. Muller cell production of insulin-like growth factor binding proteins in vitro: modulation with phenotype and growth factor stimulation. Invest Ophthalmol Vis Sci. 2004; 45(12):4535-4542.
53. Collett-Soberg PF, Cohen P. The role of the insulin-like growth factor binding proteins and the IGFBP proteases inmodulating IGF action. Endocrinol Metab Clin North Am. 1996;25(3):591-614.
54. Baxter RC. Molecular aspects of insulin-like growth factor binding proteins. Advances in Molecular and Cellular Endocrinology. Vol. 1. Greenwich, CT: JAI Press, Inc.; 1997:123-159.
55. Simo R, Lecube A, Segura RM, et al. Free insulin growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2002;134(3):376-382.
56. King JL, Guidry C. Insulin-like growth factor binding proteins modulate Muller cell responses to insulin-like growth factors. Invest Ophthalmol Vis Sci. 2004;45(8):2848-2855.
57. Beattie J, Allan GJ, Lochrie JD, et al. Insulin-like growth factorbinding protein-5 (IGFBP-5): a critical member of the IGF axis. Biochem J. 2006;395(1):1-19.
58. Yang H, Chaum E. A reassessment of insulin-like growth factor binding protein gene expression in the human retinal pigment epithelium. J Cell Biochem. 2003;89(5):933-943.
59. Slomiany MG, Rosenzweig SA. IGF-1-induced VEGF and IGFBP-3 secretion correlates with increased HIF-1 alpha expression and activity in retinal pigment epithelial cell line D407. Invest Ophthalmol Vis Sci. 2004;45(8):2838-2847.
60. Slomiany MG, Rosenzweig SA. Autocrine effects of IGF-I-induced VEGF and IGFBP-3 secretion in retinal pigment epithelial cell line ARPE-19. Am J Physiol Cell Physiol. 2004;287(3):C746-C753.
61. Guidry C, Medeiros NE, Curcio CA. Phenotypic variation of retinal pigment epithelium in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2002;43(1):267-273.
62. Hunt RC, Davis AA. Altered expression of keratin and vimentin in human retinal pigment epithelial cells in vivo and in vitro. J Cell Physiol, 1990;145(2):187-199.
63. Robey HL, Hiscott PS, Grierson I. Cytokeratins and retinal epithelial cell behaviour. J Cell Sci, 1992 102(pt 2):329-340.